Advertisement
Screener

Protagenic Therapeutics, Inc.\new (PTIX) Accumulated Other Comprehensive Income

2.8 / 5 stars · 68/120 Roast Me

Protagenic Therapeutics, Inc.\new Accumulated Other Comprehensive Income

Protagenic Therapeutics, Inc.\new (PTIX) had Accumulated Other Comprehensive Income of -$129.86 thousand as of 2025-03-31, per its 10-Q filed 2025-05-13.

Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent › Accumulated Other Comprehensive Income (Loss), Net of Tax

us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2025-05-13

  • 2025-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$129.86K.
  • 2024-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$129.85K.
  • 2024-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$130.25K.
  • 2024-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$130.16K.
Period endAccumulated Other Comprehensive Income (Loss), Net of Tax
2025-03-31-$129.86K
10-Q · filed 2025-05-13
2024-12-31-$129.85K
10-Q · filed 2025-05-13
2024-09-30-$130.25K
10-Q · filed 2024-11-14
2024-06-30-$130.16K
10-Q · filed 2024-08-14
2024-03-31-$86.77K
10-Q · filed 2024-05-15
2023-12-31-$113.55K
10-K · filed 2025-03-31
2023-09-30-$617.74K
10-Q · filed 2023-11-14
2023-06-30-$586.46K
10-Q · filed 2023-08-14
2023-03-31-$628.76K
10-Q · filed 2023-05-15
2022-12-31-$676.91K
10-K/A · filed 2024-05-14
2022-09-30-$615.11K
10-Q · filed 2022-11-14
2022-06-30-$449.68K
10-Q · filed 2022-08-11
2022-03-31-$399.36K
10-Q · filed 2022-05-13
2021-12-31-$248.35K
10-K · filed 2023-03-31
2021-09-30-$172.38K
10-Q · filed 2021-11-15
2021-06-30-$170.61K
10-Q · filed 2021-08-16
2021-03-31-$171.09K
10-Q · filed 2021-05-17
2020-12-31-$171.59K
10-K · filed 2022-04-07
2020-09-30-$172.96K
10-Q · filed 2020-11-16
2020-06-30-$173.70K
10-Q · filed 2020-08-14
2020-03-31-$174.78K
10-Q · filed 2020-06-18
2019-12-31-$172.36K
10-K · filed 2021-03-25
2019-09-30-$173.12K
10-Q · filed 2019-11-14
2019-06-30-$173.09K
10-Q · filed 2019-08-14
2019-03-31-$173.39K
10-Q · filed 2019-05-16
2018-12-31-$170.54K
10-K · filed 2020-04-29
2018-09-30-$165.15K
10-Q · filed 2018-11-08
2018-06-30-$164.66K
10-Q · filed 2018-08-14
2018-03-31-$168.71K
10-Q · filed 2018-05-15
2017-12-31-$167.81K
10-K · filed 2019-03-29
2017-09-30-$166.84K
10-Q · filed 2017-11-13
2017-06-30-$173.85K
10-Q · filed 2017-08-08
2017-03-31-$179.60K
10-Q · filed 2017-05-15
2016-12-31-$181.63K
10-K · filed 2018-04-02
2016-09-30-$174.11K
10-Q · filed 2016-11-17
2016-06-30-$170.94K
10-Q · filed 2016-08-15
2016-03-31-$148.23K
10-Q · filed 2016-07-25
2015-12-31-$148.65K
10-K/A · filed 2017-05-08
2014-12-31-$147.58K
8-K/A · filed 2016-07-12
2011-09-30$32.00K
10-Q · filed 2011-11-14
2011-06-30$80.00K
10-Q/A · filed 2011-09-07
2010-12-31$42.00K
10-Q · filed 2011-11-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B
Aditxt, Inc. (ADTX)United States$0.000B
Rafael Holdings, Inc. (RFL)United States$0.000B-0.00